Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
One of the most internationally studied peptides on this page — approved in over 35 countries, and still not FDA-approved in the US.
Thymosin Alpha-1 has an evidence base that looks different from most peptides here: genuinely large, with real international regulatory approval — just not in the United States. Here's why that gap exists and what it means.
A note on regulatory status: Thymosin Alpha-1's US compounding status has moved more than once in the last few years as part of the broader FDA peptide reclassification process, and sources differ on the exact current category as of mid-2026. Confirm current status directly with the FDA's published bulk substance list before offering this compound — this is one to double-check right before publishing given how recently and repeatedly it's changed.
Thymosin Alpha-1 is a peptide derived from thymosin, a hormone produced by the thymus gland that plays a central role in immune function. As Zadaxin, it's approved in more than 35 countries — most prominently for chronic hepatitis B — with a clinical history spanning over 11,000 human subjects across more than 30 randomized trials internationally. It has never been submitted for or received full FDA approval in the United States.
Thymosin Alpha-1 activates toll-like receptor 9 (TLR9) signaling on dendritic cells, which helps drive T-cell maturation and coordinate a more effective adaptive immune response — mechanistically well-characterized compared to most compounds on this page.
This compound has one of the larger and more internationally rigorous human trial bases of anything discussed here — which is notable, because it still hasn't cleared US approval. That's a reminder that FDA approval and "well-studied" aren't the same thing: FDA approval also requires a US-specific regulatory submission and review process that Zadaxin's manufacturer hasn't completed here. The international evidence is real; it just hasn't gone through the specific US pathway.
In the international trial literature, it's generally well-tolerated, with injection-site reactions being the most common issue. As an immune-modulating compound, it warrants caution in anyone with autoimmune disease or on immunosuppressive therapy, which a provider needs to screen for directly.
Thymosin Alpha-1's evidence base is unusually strong for a peptide without US approval — the gap here is regulatory pathway, not scientific rigor. That's still not the same as a US approval, and the compounding eligibility should be verified fresh given how much this specific compound's status has moved recently.
Regulatory status as of 2026-07-20.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense Thymosin Alpha-1 or any medication.